Seeking Alpha

InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug...

InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug Esbriet has been delayed. Last week, ITMN said it didn't expect enrollment for the Phase 3 clinical trial to be completed until the end of 2012; it had previously forecast enrollment would be completed in Q2. Citing the delay, Jefferies and Leerink Swann cut price targets on the shares.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)